Targeted protein degradation is a novel pharmacology established by drugs that recruit
target proteins to E3 ubiquitin ligases. Based on the structure of the degrader and the target …

PROteolysis TArgeting Chimeras (PROTACs) are hetero-bifunctional small molecules that
can simultaneously recruit target proteins and E3 ligases to form a ternary complex …

Chemically induced proximity between certain endogenous enzymes and a protein of
interest (POI) inside cells may cause post-translational modifications to the POI with …

Proteolysis targeting chimeras (PROTACs) are heterobifunctional ligands that mediate the
interaction between a protein target and an E3 ligase, resulting in a ternary complex, whose …

Molecular glues are small molecules that simultaneously bind to two proteins, creating a
chemically induced protein–protein interface. CELMoDs (cereblon E3 ligase modulators) …

Proteolysis targeting chimera (PROTAC) is a novel drug modality that facilitates the
degradation of a target protein by inducing proximity with an E3 ligase. In this work, we …

Targeted protein degradation is a new pharmacologic paradigm established by drugs that
recruit target proteins to E3 ubiquitin ligases via a ternary ligase-degrader-target complex …

The therapeutic strategy of targeted protein degradation (TPD) has undergone a massive
growth in interest over the last several years. Founded in 2015, C4 Therapeutics was one of …

The discovery and design of new drugs requires extensive experimental assays that are
usually very expensive and time-consuming. To cut down the cost and time of the drug …

Conformational sampling of complex biomolecules is an emerging frontier in drug discovery.
Indeed, advances in lab-based structural biology and related computational approaches like …